HiFiBiO Therapeutics Secures $37.5 Million Series B Financing to Accelerate Pipeline of Novel Antibody Drugs to Treat Cancer and Autoimmune Disorders
Home » HiFiBiO Therapeutics Secures $37.5 Million Series B Financing to Accelerate Pipeline of Novel Antibody Drugs to Treat Cancer and Autoimmune Disorders
HiFiBiO Therapeutics Secures $37.5 Million Series B Financing to Accelerate Pipeline of Novel Antibody Drugs to Treat Cancer and Autoimmune Disorders2018-05-162018-05-18http://redpeppermergers.com/wp-content/uploads/rpm-white-red-1.pngRedPepper Mergershttp://redpeppermergers.com/wp-content/uploads/rpm-white-red-1.png200px200px
VIEW ARTICLE If you would like to know more regarding the topic in this blog post, please do not hesitate to contact us.